UY28903A1 - Nuevos derivados de piridazinona - Google Patents

Nuevos derivados de piridazinona

Info

Publication number
UY28903A1
UY28903A1 UY28903A UY28903A UY28903A1 UY 28903 A1 UY28903 A1 UY 28903A1 UY 28903 A UY28903 A UY 28903A UY 28903 A UY28903 A UY 28903A UY 28903 A1 UY28903 A1 UY 28903A1
Authority
UY
Uruguay
Prior art keywords
piridazinona
compounds
new derivatives
kinase
inhibitors
Prior art date
Application number
UY28903A
Other languages
English (en)
Inventor
Dr Hoelder Swen
Dr Mueller Gunter
Dr Schoenafinger Karl
Dr Will David William
Dr Matter Hans
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of UY28903A1 publication Critical patent/UY28903A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se refiere a compuestos según la fórmula general (I), especificándose las definiciones de los sustituyentes X, R1 y R2 en la Memoria Descriptiva, así como a sus sales fisiológicamente aceptables, a métodos para producir estos compuestos, y a su uso como productos farmacéuticos. Estos compuestos son inhibidores de cinasa, en particular inhibidores de la cinasa CDK2 (cinasa 2 dependiente de ciclina).
UY28903A 2004-05-18 2005-05-17 Nuevos derivados de piridazinona UY28903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04011735A EP1598348A1 (en) 2004-05-18 2004-05-18 Novel pyridazinone derivatives as inhibitors of CDK2

Publications (1)

Publication Number Publication Date
UY28903A1 true UY28903A1 (es) 2005-12-30

Family

ID=34925033

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28903A UY28903A1 (es) 2004-05-18 2005-05-17 Nuevos derivados de piridazinona

Country Status (14)

Country Link
US (2) US7507734B2 (es)
EP (2) EP1598348A1 (es)
JP (1) JP4842261B2 (es)
KR (1) KR20070014180A (es)
CN (1) CN1972930A (es)
AR (1) AR049100A1 (es)
AU (1) AU2005243493A1 (es)
BR (1) BRPI0510151A (es)
CA (1) CA2567154A1 (es)
IL (1) IL178968A0 (es)
MX (1) MXPA06013387A (es)
TW (1) TW200607805A (es)
UY (1) UY28903A1 (es)
WO (1) WO2005111019A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
ES2469990B1 (es) * 2012-12-19 2015-01-26 Universidade De Vigo Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
CN109568256A (zh) * 2018-12-21 2019-04-05 江西润泽药业有限公司 一种cdk抑制剂注射液及其制备方法
CN111533735A (zh) * 2020-05-08 2020-08-14 张建蒙 氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN114042069A (zh) * 2021-10-22 2022-02-15 陕西国际商贸学院 一种5-取代哒嗪-4-胺衍生物、制备方法和用途
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353905A (en) 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
HU190412B (en) 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
DE4324580A1 (de) * 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
TR200201051T2 (tr) * 1999-10-19 2002-09-23 Merck & Co., Inc. Tirosin kinaz inhibitörleri.
CA2422371C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2005022972A (ja) * 2001-05-16 2005-01-27 Teikoku Hormone Mfg Co Ltd ４−（４−ピリダジニル）ピラゾール誘導体
DE10133399A1 (de) 2001-07-13 2003-01-23 Cognis Deutschland Gmbh Zusammensetzung auf Wachsbasis
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
US20040142932A1 (en) * 2002-01-18 2004-07-22 Michael Hepperle Substituted pyridazinones
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
US20090130209A1 (en) 2009-05-21
WO2005111019A1 (en) 2005-11-24
US7507734B2 (en) 2009-03-24
JP2008509884A (ja) 2008-04-03
EP1751141A1 (en) 2007-02-14
MXPA06013387A (es) 2007-06-22
BRPI0510151A (pt) 2007-10-02
IL178968A0 (en) 2007-03-08
CN1972930A (zh) 2007-05-30
AR049100A1 (es) 2006-06-28
KR20070014180A (ko) 2007-01-31
EP1598348A1 (en) 2005-11-23
AU2005243493A1 (en) 2005-11-24
TW200607805A (en) 2006-03-01
US20070259870A1 (en) 2007-11-08
JP4842261B2 (ja) 2011-12-21
US7968546B2 (en) 2011-06-28
CA2567154A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
UY28903A1 (es) Nuevos derivados de piridazinona
UY28902A1 (es) Derivados de piridazinona, métodos para producirlos y su uso como productos farmacéuticos
UY28783A1 (es) Nuevos derivados de 4-benzimidazol-2-il-piridacin-3-ona
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
ECSP099327A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso
CR11826A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY29039A1 (es) Nuevos derivados amino de urea cíclicos, su preparación y su uso farmacéutico como inhibidores de quinasa
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
ECSP077259A (es) Derivados de pirimidina
UY29337A1 (es) N-aminometilensulfonamidas sustituidas, su preparación y su uso como medicamentos.
UY29038A1 (es) Nuevos derivados de urea cíclicos sustituidos, su preparación y su uso farmacéutico como inhibidores de quinasa
UY29037A1 (es) Nuevos derivados de urea cíclicos sustituidos con heterociclo, su preparación y su uso farmacéutico como inhibidores de quinasa
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
CR10148A (es) Derivados de las benzamidas y heteroarenos
UY28745A1 (es) Nuevos compuestos
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1